Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Aceso Life Science Holding
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialize Promethera®'s therapeutic products (cell therapies and antibodies developed by Promethera® Group) in China and Southeast Asia.
Product Name : HepaStem
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 17, 2020
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Aceso Life Science Holding
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is open for recruitment and aims to include 363 patients with ACLF at 110 study sites across 22 countries in Europe.
Product Name : HepaStem
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 08, 2020
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
